Elzanor 12.5/1000mg Tablet 14s

Metformin primarily works by reducing glucose production in the liver through the inhibition of gluconeogenesis and glycogenolysis. It enhances insulin sensitivity, allowing cells to utilize glucose more effectively. On the other hand, Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, acts by blocking glucose reabsorption in the proximal tubules of the kidneys. This mechanism increases glucose excretion in urine, thereby lowering blood glucose levels and improving glycemic control. The combined effect of these two drugs provides a synergistic approach to managing blood sugar levels in patients with type 2 diabetes.